• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

Message on the passing of Dr Alwyn Mwinga from DNDi Executive Director Dr Luis Pizarro

6 Sep 2024

A message from DNDi Executive Director Dr Luis Pizarro:

We are deeply saddened by news of the death of DNDi Board Member Dr Alwyn Mwinga.

Dr Mwinga first joined DNDi’s Board in 2015, and over the last nine years served as the patient representative. It was a privilege to work alongside Dr Mwinga, and see first-hand how she brought her life-long dedication to patient rights and well-being to passionately support DNDi’s mission that no patient should be left behind.

Dr Mwinga will be remembered fondly for giving a much-needed voice to patients whose needs would otherwise have been neglected. On behalf of the whole DNDi team, I send my sincere condolences to her friends, family, and everyone who knew and worked with her.

Alwyn Mwinga

Dr Alwyn Gladwyn Zebron Mwinga was the Chief Executive Officer of the Zambia AIDS Related Tuberculosis Project (Zambart). Before joining Zambart, she worked in different capacities at CDC Zambia. She was an Expert Consultant on TB/HIV Research Priorities for the WHO in addition to serving as a member of multiple national and international boards relating to TB. She was an Associate Editor of The Lancet Infectious Diseases and the International Journal of Tuberculosis and Lung Diseases and a Senior Lecturer at the University of Zambia.

In 2007, Dr Mwinga was awarded the Global Health Achievement by the Office of Global Health CDC as well as the PEPFAR Lifetime Achievement Award in 2011 in recognition of her contribution to HIV and TB.

She studied Tropical Medicine (M.Sc.) at the University of London, and she had a M.Med and MB ChB from the University of Zambia. In 2013 she completed her PG Diploma in Bioethics at the University of Stellenbosch.

Read, watch, share

Loading...
Stories
16 Jul 2026

Annie Liang: How students’ advocacy helped bring mycetoma out of the shadows

Publications
16 Jul 2026

DNDi 2025 Annual Report

Laboratory of Medicinal and Computational Chemistry (LQMC), São Paulo University USP, São Carlos Campus, São Paulo Brazil.
Press releases
13 Jul 2026

DNDi welcomes continued GHIT support for collaboration on dengue and Zika virus drug discovery with Eisai and new partner, the Japan Institute for Health Security 

Chepokarial Rubben attentively cares for her five-year-old son, Romanu Kiptoo, at the kala-azar ward of Kacheliba Sub-County Referral Hospital in West Pokot County, Kenya. She gently soothes him, offering comfort as he endures the painful treatment for kala-azar.
Press releases
13 Jul 2026

DNDi welcomes GHIT support to advance novel oral drug candidate for leishmaniasis, accelerating progress towards elimination goals

Press releases
8 Jul 2026

Brazil, Malaysia, and Thailand set to start global clinical trial to test promising dengue treatment developed by Serum Institute of India

Patricia, 44, from Area 44 in Lilongwe, Malawi, has lived with vision loss for 10 years following a late diagnosis of cryptococcal meningitis.
Stories
30 Jun 2026

Cryptococcal meningitis: Africa’s neglected HIV killer

News
29 Jun 2026

Eric Easom, Dr Marcus Lacerda, and Mathieu Lamiaux join the DNDi Board of Directors 

Publications
29 Jun 2026

Advancing global health innovation through Europe-Africa collaboration

VIEW ALL

Help neglected patients

To date, we have delivered fourteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Youtube X-twitter Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license